IMV (TSE:IMV) is scheduled to post its quarterly earnings results before the market opens on Friday, August 9th. Analysts expect IMV to post earnings of C($0.13) per share for the quarter.
IMV (TSE:IMV) last released its quarterly earnings results on Thursday, May 9th. The company reported C($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of C($0.15) by C$0.02. The business had revenue of C$0.08 million during the quarter.
TSE:IMV opened at C$3.21 on Thursday. The company has a debt-to-equity ratio of 38.37, a quick ratio of 6.50 and a current ratio of 7.03. IMV has a one year low of C$3.06 and a one year high of C$8.49. The stock has a 50-day simple moving average of C$3.88. The firm has a market capitalization of $160.90 million and a PE ratio of -5.83.
Separately, B. Riley reiterated a “buy” rating on shares of IMV in a research note on Wednesday, May 29th.
IMV Company Profile
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.
Featured Article: Why Invest in Dividend Achievers?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.